Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.

The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.

The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.

Crushing spironolactone pills and combining them with minoxidil for topical application may be effective for hair loss, with the addition of finasteride suggested. Adding rosemary and peppermint oils can help mask the unpleasant smell.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

The conversation is about a user starting a hair loss treatment with Dutasteride, Minoxidil, and RU58841, hoping to prevent baldness. Other users comment on the user's current hair condition and the intensity of the chosen treatment.

The user is considering minoxidil, clascoterone, and fluridil for hair loss, avoiding finasteride and RU58841. They are also contemplating a hair transplant and exploring the resilience of transplanted hair without finasteride.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

A user's experience with using stemoxydine, minoxidil, and finasteride together as a hair loss treatment stack.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses the idea of naturally lowering testosterone levels to potentially reduce DHT and help with hair loss, though it is speculative and not tested by the original poster. Participants suggest using treatments like finasteride, dutasteride, or RU58841 instead, as they directly target DHT without reducing testosterone.

Hair loss treatments, specifically experiences with Redensyl as well as other treatments such as Minoxidil, finasteride and RU58841.

A humorous discussion about random, long hairs appearing on the body, with no connection to hair loss treatments like Minoxidil, finasteride, or RU58841. Participants share personal anecdotes about these unusual hairs.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

Taking too much Zinc, around 30mg per day, might cause hair loss. The user is also using 0.5mg Dutasteride and 2.5mg Oral Minoxidil daily.

The conversation is about a person sharing before and after pictures of their hair loss treatment, which includes Minoxidil, Finasteride, and Dutasteride. They discuss their own hair loss, particularly the recession of their temporal points.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The user plans to switch from dutasteride back to finasteride due to worsening hair loss, possibly due to increased scalp testosterone. Others report mixed results with both treatments, showing individual variability.